

Markers of cardiovascular risk are not changed by increased whole-grain intake: the WHOLEheart study, a randomised, controlled dietary intervention

Iain A. Brownlee¹, Carmel Moore², Mark Chatfield², David P. Richardson³, Peter Ashby⁴, Sharron A. Kuznesof¹, Susan A. Jebb² and Chris J. Seal^{1*}

¹School of Agriculture, Human Nutrition Research Centre, Food & Rural Development, Newcastle University, Newcastle upon Tyne NE1 7RU, UK

²Elsie Widdowson Laboratory, MRC Human Nutrition Research, Fulbourn Road, Cambridge CB1 9NL, UK

³DPR Nutrition, 34 Grimwade Avenue, Croydon, Surrey CR0 5DG, UK

⁴Cereal Partners Worldwide, 2 Albany Place, 28 Bridge Road East, Welwyn Garden City, Hertfordshire AL7 1RR, UK

(Received 14 October 2009 – Revised 14 January 2010 – Accepted 18 January 2010 – First published online 23 March 2010)

Recommendations for whole-grain (WG) intake are based on observational studies showing that higher WG consumption is associated with reduced CVD risk. No large-scale, randomised, controlled dietary intervention studies have investigated the effects on CVD risk markers of substituting WG in place of refined grains in the diets of non-WG consumers. A total of 316 participants (aged 18–65 years; BMI > 25 kg/m²) consuming < 30 g WG/d were randomly assigned to three groups: control (no dietary change), intervention 1 (60 g WG/d for 16 weeks) and intervention 2 (60 g WG/d for 8 weeks followed by 120 g WG/d for 8 weeks). Markers of CVD risk, measured at 0 (baseline), 8 and 16 weeks, were: BMI, percentage body fat, waist circumference; fasting plasma lipid profile, glucose and insulin; and indicators of inflammatory, coagulation, and endothelial function. Differences between study groups were compared using a random intercepts model with time and WG intake as factors. Although reported WG intake was significantly increased among intervention groups, and demonstrated good participant compliance, there were no significant differences in any markers of CVD risk between groups. A period of 4 months may be insufficient to change the lifelong disease trajectory associated with CVD. The lack of impact of increasing WG consumption on CVD risk markers implies that public health messages may need to be clarified to consider the source of WG and/or other diet and lifestyle factors linked to the benefits of whole-grain consumption seen in observational studies.

Wholegrain foods: CVD risk: LDL-cholesterol: Dietary intervention

Data from observational studies show that increased whole-grain food consumption is strongly associated with a lower relative risk of CVD^(1–5). In addition, cross-sectional studies have suggested a favourable association between wholegrain food intake and markers of cardiovascular health^(6–8).

These observational data led to health claims for use on wholegrain foods in the USA⁽⁹⁾, UK⁽¹⁰⁾ and Sweden⁽¹¹⁾. In each case, the claims relate to a reduction in subsequent risk of heart disease (or the maintenance of a healthy heart) for those consuming whole grains. The health claims are based on whole grains as a category, and do not make a distinction between different grain varieties or their relative benefits. Consumers are advised simply to consume more ‘whole grains’ and are provided with a list of foods and products containing whole grain. For some cereals, such as oats and barley, there are observational and intervention data suggesting that bran and some soluble fibre components improve plasma cholesterol concentrations and other markers of cardiovascular health⁽¹²⁾. However, evidence that consumption of mixed sources of wholegrain foods as replacements for refined-grain foods has similar benefits is limited. In a randomised,

cross-over feeding trial, eleven overweight or obese hyper-insulinaemic subjects were fed diets based on either refined grain or whole grain for two 6-week periods. A reduction in average fasting insulin concentrations was observed, and the majority of participants had increased insulin sensitivity (as measured by a euglycaemic–hyperinsulinaemic insulin clamp) at the end of the whole-grain diet period⁽¹³⁾. In contrast, no change in insulin sensitivity was seen using the same methodology in a randomised, cross-over study comparing wholegrain or refined-grain food consumption over 6 weeks in thirty overweight participants⁽¹⁴⁾. In this second study, consumption of wholegrain foods also had no significant effect on serum lipids, markers of lipid peroxidation, blood pressure or markers of inflammation. Two recent studies have suggested that intervention with wholegrain foods, in combination with either the Step I American Heart Association⁽¹⁵⁾ or a hypoenergetic⁽¹⁶⁾ dietary regimen, was more beneficial to markers of CVD risk (diastolic and mean arterial blood pressure in Behall *et al.*⁽¹⁵⁾ and C-reactive protein and percentage abdominal fat in Katcher *et al.*⁽¹⁶⁾) than intervention with the low-fat-dietary regimen alone. Thus, although

* Corresponding author: Professor Chris Seal, fax +44 191 222 6720, email chris.seal@ncl.ac.uk

there are strong observational data to support the health benefits of increased whole-grain consumption, data from small-scale interventions are conflicting and direct evidence from intervention studies carried out in large numbers of subjects is not available. This is highlighted by two recent systematic reviews, which both concluded that there is a lack of randomised, controlled evidence demonstrating a beneficial effect of mixed sources of wholegrain foods on CVD risk^(17,18). No previous intervention studies have specifically tested the impact of increasing whole-grain intake among participants who habitually consume refined grains; the effect of increased wholegrain food consumption is instead compared with a refined-grain cross-over- or washout period. Previous reports would suggest that whole-grain intake in the UK population is generally low, with about a third of British adults eating no whole grains, and less than 5% consuming three servings of whole grains daily⁽¹⁹⁾.

We hypothesised that increasing the consumption of a variety of wholegrain foods by individuals not routinely consuming such foods would result in improvements to measures of CVD risk. Accordingly, we conducted a randomised, parallel-group dietary intervention to evaluate the effect of substituting refined-grain foods for wholegrain foods in the diet of habitual refined-grain consumers on markers of CVD risk to inform the development of dietary guidelines. The primary outcome measure was change in fasting plasma LDL-cholesterol concentration, a standard marker of CVD risk⁽²⁰⁾. Secondary outcome measures were change in fasting lipid profile, measures of insulin sensitivity, inflammatory and haemostatic measures, blood pressure and body weight.

Methods

Project ethical approval and registration

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the Newcastle and North Tyneside Local Research Ethics Committee 1 (reference 05/Q0905/75) and by the Newcastle upon Tyne Hospitals NHS Foundation Trust R&D Department. Written informed consent was obtained from all subjects/patients. The study was registered with isrctn.org (ISRCT no. CCT-NAPN-A13175).

Study participants

A total of 316 participants, aged 18–65 years, were recruited for the study in two UK centres (Newcastle upon Tyne and Cambridge). Exclusion criteria were: (1) BMI below 25 kg/m²; (2) habitual consumption of >30 g whole grain per d (i.e. >1.5 servings per d), as assessed by a retrospective 1-week FFQ; (3) previous diagnosis of CVD or diabetes, or treatment for hyperlipidaemia; (4) smoking more than twenty cigarettes per d, or with a history of substance abuse. Those reporting recent weight change (≥ 3 kg), desire to diet or planning an extended period away from the study centres were also excluded.

Participants were recruited by advertisements in the local press, posters and by invitation letters through local primary care practices. Initial screening was carried out by telephone

interview. Those thought to be suitable completed a FFQ to quantify whole-grain intake during the previous week and were subsequently invited for further screening (of BMI) at the research facility.

Details of study enrolment and completion are summarised in Fig. 1. Although there were a significantly higher number of dropouts in the intervention groups, the majority of these discontinued the study before completion of baseline measurements (i.e. before the wholegrain food intervention had commenced), mainly as a result of lack of motivation. Only six participants withdrew due to the study foods (three in each intervention group), suggesting that the intervention was generally well accepted in this population group.

Intervention design

A previous feasibility (uncontrolled, non-randomised) study at Newcastle University (AR Jones and CJ Seal, unpublished results) demonstrated a reduction in both total and LDL-cholesterol concentrations following 8 weeks of a whole-grain intervention at intakes of approximately 70 g whole grain per d in twenty-two male and female subjects. The change in LDL-cholesterol (about 10%) concentration was greater than predicted from the Framingham Offspring Study⁽⁸⁾ in which a 4% difference in fasting LDL-cholesterol concentration was observed between the lowest (median intake less than one serving of whole grain per d) and highest (median intake approximately three servings of whole grain per d) quintiles of whole-grain consumption. These data were used in conjunction with data from a previous project carried out at the Medical Research Council's collaborative centre for Human Nutrition Research (MRC-HNR), Cambridge (Food Standards Agency no. N02026) to estimate the sample size. Both sets of data were derived from overweight study participants, i.e. similar to those selected for the WHOLEheart study, to give an appropriate estimate of variance.

On the basis of the estimates of variance from the two previous studies, a sample size of 254 subjects was calculated to detect a 10% decrease in LDL-cholesterol with a 0.05 significance level and 80% power, assuming an SD of 0.85. Allowing for an estimated dropout rate of 15% (based on similar nutrition intervention studies in the two centres), a target of 100 subjects per treatment group was proposed.

Participants were randomly allocated (using an MS-DOS-based computer program at each study centre) to the three study groups for a 16-week intervention using a procedure that ensured an even distribution of participants within each group by age, sex and BMI. A single research staff member at each centre was responsible for recruitment, allocating participants by minimisation, giving participants instructions and providing them with study foods, and taking anthropometric measurements to agreed standard operating procedures. Participants in the control group were asked to maintain their current diet throughout the 16-week period. The two intervention groups were provided with a range of wholegrain foods (see Table 1), and asked to substitute these 'like-for-like' for refined-grain foods in their diet to a prescribed amount over the intervention period. Participants in intervention group 1 were asked to consume the equivalent of 60 g whole grain per d (approximately equal to the whole-grain content of




Fig. 1. Enrolment details for the WHOLEheart study. WG, whole-grain.

three slices of bread) for the whole 16-week period; participants in intervention group 2 were asked to consume 60 g whole grain per d for 8 weeks followed by 120 g whole grain per d for the final 8 weeks of the intervention.

Study foods

Participants were given the wholegrain foods shown in Table 1. Foods were provided on-demand at approximately

fortnightly intervals, and were either delivered to volunteers or collected in person by the participants during measurement visits. The wholegrain foods were selected from the small range of wholegrain foods readily available in the UK at the time of starting the intervention. Participants were given free choice as to which wholegrain foods they selected to achieve the target levels of intake for each intervention group (see below). This approach was chosen to best reflect choices of wholegrain foods in a free-living population, similar to those

Table 1. Whole-grain content of foods provided to WHOLEheart participants

Product name	Whole-grain content (g per 100 g)	Portion size (g)		Whole-grain weight (g/portion)	
		Male	Female	Male	Female
Wholewheat bread	54.8	37	37	20.0	20.0
Shredded Wheat Fruitful	57.6	67	59	38.6	34.0
Cheerios	64.3	43	35	27.6	22.5
Porridge oats	11.2*	254*	216*	28.4	24.2
Brown basmati rice	34	220*	181*	74.8	61.5
Wholewheat pasta	30.9	257*	200*	79.4	61.8
Weetabix	80.8	42	36	33.8	29.0
Seriously Oaty porridge	52.8	38	38	20.0	20.0
Quaker Oat Bar	60	38	38	22.8	22.8
SunChips (wholegrain crisps)	69	29	29	19.8	19.8

* Denotes cooked weight, whereas all other whole-grain contents are per 100 g dry weight.

reported in observational studies. The whole-grain content of these foods was described to study participants in whole-grain servings, where one serving was equivalent to the whole-grain content of one slice of wholemeal bread (approximately 20 g). However, a portion (the amount of food eaten at a sitting) could contain more than one serving of whole grains (for example, a portion of brown rice contained 3–3.5 servings, or 60–70 g, of whole grain). The target for intervention group 1 was to consume three servings of whole grain per d throughout the 16 weeks of the intervention. For intervention group 2 the target was three servings per d for the first 8 weeks then six servings per d for the second 8 weeks of the intervention. Where possible, foods were packaged into portion sizes appropriate for male and female participants based on typical portions reported in the UK National Diet and Nutrition Survey data and other data from cohort studies carried out in Newcastle⁽²¹⁾. The number of whole-grain servings was indicated on the packaging. In other cases, foods were provided in manufacturers' packaging, and details of the whole-grain content were given in participant study guides. Participant whole-grain intake was assessed by FFQ at week 0 (baseline), week 8 and week 16. The FFQ was a 149-item questionnaire, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) FFQ and asking for consumption of foods during the preceding 7 d only. The WHOLEheart FFQ was expanded to include inputs for both the wholegrain foods provided for the study, and for other

wholegrain foods available in the UK. Participants were given checklists and calendars to mark off their consumption of servings of whole grain to aid compliance.

Blood sampling and anthropometric measurement

All measurements were made at week 0 (baseline), week 8 and week 16. Each time-point included: duplicate fasting blood samples (within 7 d of each other); seated resting blood pressure (assessed twice on the same day, 5 min apart); waist circumference, measured at the mid-point between the lower rib margin and the iliac crest; BMI and body fat percentage, assessed using a Tanita BC-418 segmental body composition analyser (Tanita Corporation of America Inc., Arlington Heights, IL, USA)⁽²²⁾.

Plasma sample analysis

Analysis of plasma fibrinogen and plasminogen activator inhibitor-1 were conducted at the Department of Clinical Biochemistry at Addenbrooke's Hospital, Cambridge, UK. All other measures of plasma CVD risk markers were analysed by the Nutritional Biomarker Analysis group at the MRC-HNR unit in Cambridge, UK using standard analytical procedures (under ISO 9001 accreditation). Further details of these analyses are included in Table 2.

Table 2. Markers of CVD risk analysed in fasting plasma samples. All measurements were made at week 0, week 8 and week 16 of the intervention period

Outcome measure	Detection method	Reference
Lipid profile		
Total cholesterol	Enzymic colorimetric assay	Wesenberg <i>et al.</i> (2000) ⁽³⁰⁾
HDL-cholesterol	Colorimetric assay	Wesenberg <i>et al.</i> (2000) ⁽³⁰⁾
LDL-cholesterol	Indirect calculation (Friedwald equation), based on measured levels of TAG, total and HDL-cholesterol	Nandeesh <i>et al.</i> (2006) ⁽³¹⁾
TAG	Enzymic colorimetric assay	Amsel <i>et al.</i> (2001) ⁽³²⁾
NEFA	Enzymic colorimetric assay using commercially available kit (catalogue no. 11 383 175 001; Roche Diagnostics, Burgess Hill, West Sussex, UK)	Shimizu <i>et al.</i> (1980) ⁽³³⁾
Insulin sensitivity		
Glucose	Colorimetric assay	Savoca <i>et al.</i> (2006) ⁽³⁴⁾
Insulin	Fluorometric immunoassay using commercially available kit (catalogue no. B080–101; Dako Ltd, Ely, Cambs, UK)	Andersen <i>et al.</i> (1993) ⁽³⁵⁾
Modified QUICKI	Indirect measurement based on measured glucose, insulin and NEFA levels	Katz <i>et al.</i> (2000) ⁽³⁶⁾ , Rabasa-Lhoret <i>et al.</i> (2003) ⁽³⁷⁾
Endothelial function		
ICAM-1	Colorimetric sandwich ELISA using commercially available kit (catalogue no. SBBE1B; R&D Systems, Abingdon, Oxon, UK)	Register <i>et al.</i> (2004) ⁽³⁸⁾
VCAM-1	Colorimetric sandwich ELISA using commercially available kit (catalogue no. SVC00; R&D Systems, Abingdon, Oxon, UK)	Garton <i>et al.</i> (2003) ⁽³⁹⁾
E-selectin	Colorimetric sandwich ELISA using commercially available kit (catalogue no. SBBE2B; R&D Systems, Abingdon, Oxon, UK)	Ruchaud-Sparagano <i>et al.</i> (1998) ⁽⁴⁰⁾
Inflammatory status		
Sialic acid	Enzymic colorimetric assay using commercially available kit (catalogue no. 10 784 192 001; Roche Diagnostics, Burgess Hill, West Sussex, UK)	Webber <i>et al.</i> (2006) ⁽⁴¹⁾
CRP	Particle-enhanced, turbidimetric immunoassay	Roberts <i>et al.</i> (2001) ⁽⁴²⁾
IL-6	Colorimetric sandwich ELISA using commercially available kit (catalogue no. 850-035-096; Diaclone SAS, Besançon, France)	Wehlin <i>et al.</i> (2004) ⁽⁴³⁾
Fibrinogen	Modified Clauss methodology	Al-Barjas <i>et al.</i> (2006) ⁽⁴⁴⁾
PAI-1	Colorimetric sandwich ELISA using commercially available kit (Technozym [®] PAI-1 Actibind [®] ; Technoclone, Dorking, Surrey, UK)	Pannekoek <i>et al.</i> (1986) ⁽⁴⁵⁾

QUICKI, quantitative insulin sensitivity check index; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor.

Table 3. Outcome measures for the WHOLEheart study*
(Median values and standard deviations)

	Baseline						Week 8						Week 16						
	Control		Intervention 1		Intervention 2		Control		Intervention 1		Intervention 2		Control		Intervention 1		Intervention 2		
	Median	SD	Median	SD	Median	SD	Median	SD	Median	SD	Median	SD	Median	SD	Median	SD	Median	SD	
Minimisation																			
Age	45.6	10	45.9	10.1	45.7	9.9	–	–	–	–	–	–	–	–	–	–	–	–	
Percentage male	49.0		50.0		51.2		–	–	–	–	–	–	–	–	–	–	–	–	
BMI (kg/m ²)	30.0	4.0	30.0	3.7	30.3	4.5	–	–	–	–	–	–	–	–	–	–	–	–	
Anthropometry																			
Weight (kg)	86.7	14.0	86.7	14.2	86.0	13.2	87.1	14.0	86.9	14.5	86.3	13.2	86.7	13.8	87.4	14.8	86.2	13.0	
Body fat (%)	34.6	9.1	34.0	8.3	33.3	9.4	34.2	9.1	34.8	8.5	33.4	9.1	34.9	9.0	35.0	8.2	33.6	9.5	
Systolic BP (mmHg)	127.3	14.8	125.5	16.1	129.5	15.5	126.0	15.0	125.5	16.9	127.3	16.3	124.3	14.9	123.5	17.4	126.8	16.2	
Diastolic BP (mmHg)	79.8	10.2	79.0	9.8	79.0	9.3	78.5	10.5	78.8	10.6	77.5	10.3	77.0	9.7	76.5	10.0	77.8	10.1	
Lipid profile																			
Total cholesterol (mmol/l)	5.2	1.0	5.1	0.8	5.3	1.0	5.2	1.1	5.2	0.8	5.4	1.0	5.4	1.0	5.2	0.9	5.5	1.1	
HDL-cholesterol (mmol/l)	1.3	0.3	1.3	0.3	1.3	0.2	1.3	0.3	1.3	0.3	1.3	0.3	1.4	0.3	1.3	0.3	1.3	0.3	
LDL-cholesterol (mmol/l)	3.2	0.9	3.2	0.7	3.3	0.8	3.1	0.9	3.2	0.7	3.3	0.8	3.2	0.9	3.3	0.8	3.4	0.9	
TAG (mmol/l)	1.5	1.0	1.4	0.8	1.4	0.8	1.4	0.9	1.4	1.0	1.3	0.9	1.4	0.8	1.3	0.9	1.5	0.8	
NEFA (mmol/l)	0.52	0.23	0.55	0.19	0.51	0.2	0.50	0.18	0.54	0.21	0.48	0.19	0.50	0.2	0.51	0.17	0.44	0.20	
Insulin sensitivity																			
Glucose (mmol/l)	5.5	0.5	5.6	0.7	5.4	0.7	5.5	0.6	5.5	0.8	5.5	0.8	5.5	0.6	5.4	1.0	5.4	0.5	
Insulin (pmol/l)	59.2	34.3	53.7	53.4	49.6	33.0	62.3	47.2	55.8	58.1	54.2	30.8	59.6	66.1	50.5	46.0	57.7	32.1	
Modified QUICKI	0.38	0.06	0.38	0.05	0.40	0.05	0.39	0.05	0.39	0.04	0.39	0.05	0.38	0.05	0.39	0.04	0.39	0.05	
Endothelial function																			
ICAM-1 (ng/ml)	222	52.1	215	41.4	221	46.3	222	59.2	223.0	39.0	225	50.6	231	58.4	219	45.8	229	57.8	
VCAM-1 (ng/ml)	661	135	686	141	711	131	663	130	667	139	687	138	667	140	670	146	687	143	
E-selectin (ng/ml)	32.3	13.3	30.3	13.7	30.2	13.0	32.0	11.9	32.0	11.9	29.7	13.6	35.1	12.8	35.1	12.8	30.5	14.0	
Inflammatory status																			
Sialic acid (mg/l)	671	83	683	82	701	93	668	89	691	75	704	89	671	92	676	78	691	102	
CRP (mg/l)	2.4	2.3	2.4	9.9	3.2	4.6	2.7	2.8	2.6	2.5	3.5	7.2	2.9	3.5	3.1	4.3	3.2	5.9	
Fibrinogen (g/l)	3.1	0.6	3.1	0.7	3.2	0.8	3.0	0.7	3.2	0.7	3.3	0.9	3.1	0.6	3.2	0.7	3.2	0.9	
PAI-1 (ng/ml)	18.1	42.9	14.4	40.9	11.6	27.9	18.3	35.8	16.1	34.3	15.0	35.2	17.0	31.2	13.9	30.6	12.7	31.4	

Wholegrain food intervention and CVD risk

BP, blood pressure; QUICKI, quantitative insulin sensitivity check index; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1.
* Age, sex (percentage male) and BMI were used in participant randomisation.

Table 4. Effect of wholegrain intervention on biomarkers of cardiovascular health

(Percentage change compared with the control group and 95% confidence intervals)

	Difference (%) from control group mean	95% CI
Lipid profile		
Total cholesterol	-0.60	-2.25, 1.09
HDL	-1.63	-3.37, 0.15
LDL (calculated)	-1.01	-3.65, 1.71
TAG	2.24	-2.88, 7.64
Insulin sensitivity		
Glucose	-0.82	-1.95, 0.32
Insulin	1.84	-4.12, 8.17
NEFA	-3.11	-9.26, 3.47
QUICKI	-0.30	-1.26, 0.66
R-QUICKI	0.62	-0.96, 2.22
Inflammatory status		
Sialic acid	0.44	-1.21, 2.12
CRP	-1.20	-12.32, 11.32
IL-6	ND	-
Coagulatory status		
Fibrinogen	1.31	-2.03, 4.76
PAI-1	-2.78	-22.12, 21.36
Endothelial function		
ICAM-1	-0.66	-2.93, 1.66
VCAM-1	-0.81	-3.39, 1.83
E-selectin	-1.46	-5.17, 2.40
Anthropometric measures		
Systolic BP	-0.73	-2.17, 0.73
Diastolic BP	-0.18	-1.99, 1.66
Weight	-0.01	-0.49, 0.46
Waist	0.1	-0.7, 0.9
Body fat percentage	0	-0.4, 0.4

QUICKI, quantitative insulin sensitivity check index; R-QUICKI, revised QUICKI; CRP, C-reactive protein; ND, not determined; PAI-1, plasminogen activator inhibitor-1; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; BP, blood pressure.

Statistical analysis

All statistical analyses were carried out using the Stata version 10.1 software package (Statacorp LP, College Station, TX, USA). All variables (except waist and body fat percentage) were log transformed before analysis. A pre-specified, random-intercepts model was used to account for the correlated nature of longitudinal measures. The intervention groups were compared with the control group at follow-up by taking the average of week 8 and week 16 data and taking the average of the two intervention groups. This was considered to be the most powerful way of detecting a statistically significant difference, and removes the need for adjusting *P* values because of multiple comparisons. The difference between both geometric means and a 95% CI are presented. If the 95% CI fell around 0, then no further analysis was carried out.

Results

The median age (46 years) and BMI (30 kg/m²) of participants completing the study were not different between groups (Table 3). Participant characteristics at baseline were similar across all groups (see Table 3), indicating good randomisation through the minimisation procedure.

Duplicate measures of C-reactive protein, lipid profiles and markers of insulin sensitivity all had Spearman's correlation values above 0.70, demonstrating good reproducibility between measurements at each time-point. Table 4 shows the effect of wholegrain intervention on fasting lipid profiles and other markers of cardiovascular risk, expressed as percentage change compared with the control group, calculated following the statistical model outlined above. Table 3 displays mean data for all outcome measures in each group at each time-point. Differences from the control group were very small and not significant (*P*>0.05) for any of the measured outcomes. Most markers were ameliorated in whole-grain consumers compared with non-whole-grain consumers, but in all cases the 95% CI spanned zero change.

As an example, LDL-cholesterol was 1.01 (95% CI -1.71, 3.65)% lower on the intervention arms than on the control diet at follow-up measurements (intervention group and week 8 and week 16 data averaged). Approximately 70% of all IL-6 measurements from the intervention period were below the minimum detectable value (0.8 pg/ml); therefore no statistical analysis was possible for this outcome measure only. Weight changes within the groups were also similar.

Participant whole-grain and dietary intake

The mean whole-grain intake of each group (estimated from FFQ data) at each time-point is shown in Fig. 2. Levels of intake were close to those prescribed, suggesting that the participants, on average, complied with the study requirements. At baseline whole-grain intake was less than 20 g per d for each group, showing that whole-grain intake was still within the screening criteria for inclusion at the commencement of the study. For the control group whole-grain intake averaged 19 (SD 19.9) g/d across the whole intervention; for intervention group 1, whole-grain intake was 74 (SD 28.5) g/d averaged for weeks 8 and 16 (no significant difference in whole-grain intake between week 8 and week 16); finally, for intervention group 2, whole-grain intake was 83 (SD 31.1) g/d at week 8 and 115 (SD 39.6) g/d at week 16.




Fig. 2. Whole-grain intake (g/d) calculated from FFQ for WHOHeart participants from screening and during the 16-week intervention. (□), Control group; (▨), intervention group 1, 60 g whole grain per d for 16 weeks; (■), intervention group 2, 60 g whole grain per d for 8 weeks, followed by 120 g whole grain per d for 16 weeks. Values are means, with standard deviations represented by vertical bars. ^{a,b,c} Mean values with unlike letters were significantly different (*P*<0.001; two-tailed unpaired non-parametric *t* test).

Table 5 shows the median daily frequency of food item consumption by participants in each group. The principal changes in whole-grain intake were reflected in an increase in the frequency of consumption of breads and breakfast cereals. In the control group, frequency of breakfast cereal consumption was lower at week 8 ($P=0.001$). Both intervention groups had higher frequencies of intakes of these food categories during the last 8 weeks of intervention for intervention group 2 ($P<0.038$). For intervention group 2 there was a significant reduction in the frequency of fruit consumption at 16 weeks compared with the control group ($P=0.045$), but otherwise frequency of intakes of other food groups were not different between intervention and control groups.

Median macronutrient intake at each time-point was estimated from FFQ data. The results are summarised in Table 6 (expressed as changes from baseline). While the wholegrain food intervention resulted in a marked increase in dietary fibre intake compared with baseline in the intervention groups (median increase of between 4.69 and 11.0 g/d), it also resulted in an increased total carbohydrate intake (median increase of about 15 g/d or above), and tended to result in an increased total energy intake (a significant increase in intervention group 1 at week 8 and intervention group 2 at week 16).

Discussion

An increase in whole-grain consumption for a 16-week period did not significantly affect any of the biomarkers of cardiovascular health assessed here. These results are consistent with previous findings of Andersson *et al.*⁽¹⁴⁾, who noted no benefit of consumption of a range of wholegrain foods (from mixed grain sources) on any marker of CVD risk⁽¹⁴⁾. The 2007 study of Andersson *et al.*⁽¹⁴⁾ is also the only randomised, controlled whole-grain intervention other than the study reported here to have a robust power calculations to determine sample size. An earlier study of similar design showed a small but significant decrease in mean fasting insulin, but no other benefits to CVD risk were evident⁽¹³⁾. Two previous studies have shown that inclusion of wholegrain foods alongside hypoenergetic dietary interventions reduced blood pressure⁽¹⁵⁾, C-reactive protein and percentage abdominal fat⁽¹⁶⁾ significantly more than hypoenergetic interventions alone. Such studies support observational data suggesting whole-grain consumption is part of a healthy lifestyle, but do not demonstrate that increased wholegrain food consumption benefits CVD risk as a single, independent dietary factor.

The biomarkers of cardiovascular health used within the present study are all well-established biochemical and anthropometric markers of CVD risk, and embody the range of physiological processes thought to be involved in disease onset. We calculated a fasting marker of insulin sensitivity based on glucose, lipid and insulin concentrations (modified quantitative insulin sensitivity check index; QUICKI). Whilst this method has been shown to be significantly correlated with more robust measures of insulin sensitivity⁽²³⁾ it may be less sensitive in detecting subtle diet-induced changes compared with direct measures such as the euglycaemic–hyperinsulinaemic clamp or intravenous glucose tolerance test. Likewise, a more detailed analysis of lipoprotein subclasses may be required to demonstrate changes in lipid metabolism.

Table 5. Daily frequency of consumption of foods in study groups throughout the intervention† (Mean values and standard deviations)

Food group	Baseline						Week 8						Week 16					
	Control		Intervention 1		Intervention 2		Control		Intervention 1		Intervention 2		Control		Intervention 1		Intervention 2	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Meat	1.28	0.76	1.28	0.81	1.28	0.69	1.14	0.79	1.28	0.70	1.14	0.97	1.14	0.7	1.14	0.72	1.27	0.89
Fish	0.28	0.44	0.42	0.33	0.28	0.34	0.28	0.34	0.28	0.28	0.33	0.28	0.28	0.28	0.35	0.30	0.28	0.27
Breads	1.57	1.39	1.33	1.57	1.36	1.16	1.35	1.72	1.89*	1.12	2.26*	1.05	1.99*	1.46	1.99*	1.15	3.06*	1.93
Breakfast cereals	0.79	0.72	0.43	0.51	0.57	0.48	0.57*	0.51	1.00*	0.59	1.00*	0.54	1.00*	0.57	0.50	0.52	1.00*	0.65
Potatoes, rice and pasta	1.28	0.62	1.28	0.52	1.28	0.49	1.29	0.52	1.28	0.47	1.28	0.49	1.28	1.21	0.56	1.28	0.53	1.29
Dairy and egg products	2.85	1.14	2.71	1.13	3.15	1.41	3.22	1.34	3.43	1.44	3.15	1.44	3.15	3.11	1.41	3.15	3.07	1.36
Milk	2.00	0.99	2.00	1.06	2.00	1.11	2.00	1.07	2.00	1.23	2.00	1.00	2.00	2.00	0.99	2.00	2.00	1.08
Spreads	1.00	1.16	0.93	1.15	1.00	1.26	0.86	1.37	1.00	1.16	1.00	1.03	1.00	0.93	1.28	1.07	1.00	1.23
Sweets and snacks	1.67	2.26	1.96	2.16	2.00	2.97	1.72	1.97	1.67	2.07	1.79	2.07	1.79	2.00	2.27	1.71	2.05	2.14
Fruit	1.63	1.38	1.43	1.55	1.79	1.87	1.71	1.25	1.33	1.26	1.21	1.64	1.21	1.58	1.65	1.29	1.00*	1.29
Vegetables	3.38	1.66	3.41	1.59	2.70	2.01	2.84	1.69	3.22	1.43	2.70	2.04	2.70	2.95	1.60	3.26	2.55	1.84

* Changes in frequencies of food consumption were significantly different from their comparator values ($P<0.05$).

† Changes in daily frequency of consumption of intervention group 1 and intervention group 2 from baseline (week 0) were compared with changes from baseline in the control group (week 0) by the non-parametric, two-sample Wilcoxon rank-sum test. Control values from week 8 and week 16 were compared with those at baseline.

Table 6. Median change from baseline in daily nutrient intakes at week 16 for each study group and *P* values v. control†

Daily intake	Week 8				Week 16			
	Control	Intervention 1	Intervention 2	<i>P</i>	Control	Intervention 1	Intervention 2	<i>P</i>
	Energy intake (kJ)	-430	379*	-399	0.015	-679	387	587*
Carbohydrate (g)	-1.97	22.6*	14.8*	0.004	-14.8	37.1*	53.8*	0.007
Protein (g)	-3.17	6.15*	1.75	0.014	-4.25	5.05	6.99*	0.061
Fat (g)	-2.87	0.245	-8.12	0.162	-4.05	-2.96	-1.63	0.546
Alcohol (g)	0.000	0.000	0.000	0.820	0.000	0.000	0.000	0.191
Percentage energy from carbohydrate	0.348	1.241*	1.838*	0.049	-0.047	3.303*	4.204*	0.002
Percentage energy from protein	0.108	0.123	0.845	0.944	-0.143	0.288	0.428	0.268
Percentage energy from fat	0.262	-1.884	-2.113*	0.033	0.114	-1.241	-3.934*	0.089
Percentage energy from alcohol	0.000	0.000	0.000	0.5594	0.000	-0.116	-0.048	0.0841
Dietary fibre (g)	-0.144	4.69*	6.23*	<0.001	0.438	5.70*	11.0*	<0.001

*Nutrient intakes were significantly different from the control values ($P < 0.05$).

† Estimates of macronutrient intake were taken from FFQ data. Changes in daily nutrient intakes of intervention group 1 and intervention group 2 were compared with changes in the control group by the non-parametric, two-sample Wilcoxon rank-sum test. Values for the control group did not significantly differ from baseline at either week 8 or week 16.

We believe that the disparity in the findings from the observational data and the present intervention study warrants further consideration and may arise as a consequence of methodological and/or biological effects. We sought wherever possible to reduce the sources of methodological errors. Intervention studies may sometimes fail to show the expected effect because the subjects fail to comply with the dietary prescription or because of unexpected changes in the control group. FFQ are not as ideal as food diaries for assessing dietary or nutrient intake, but do provide a useful means of measuring changes in frequency of the consumption of specific food types over time, and also tend to be less time intensive for participants to fill out, thereby increasing compliance. The FFQ used in the present study was designed to quantify food consumption during the 7 d before measurement days. The shorter time frame for recollection may increase the precision of the measurement tool compared with FFQ which measure diet over preceding months or up to 1 year. Results from the dietary analysis suggested that the provision of specific foodstuffs and regular contact and motivation of participants by the research team resulted in good compliance to the prescribed intake levels of whole grain in each group. However, the participants appeared to include the wholegrain foods as a dietary addition as opposed to the dietary substitution that was explicitly requested in participant guidelines and investigator instruction. Therefore, the modality of whole-grain inclusion in the diet desired for the intervention may not have been achieved. Our dietary inclusion criteria for participants were based solely on low elective wholegrain food consumption. Future whole-grain-based dietary interventions in free-living individuals may benefit from more specific inclusion criteria (for example, choosing participants who regularly consume breakfast, or those who consume high amounts of (refined) grain products within their habitual diet). This dietary effect is also relevant to the development of dietary guidelines for whole-grain consumption in the general population. These guidelines must be designed to achieve replacement of refined-grain foods in the diet without increased overall food consumption.

Intervention studies may sometimes be underpowered to detect a significant effect, but this was a large study which estimated differences with high precision (i.e. narrow 95 % CI), where no clear trend was observed. The study may have been of insufficient duration to detect an effect, but comparison of the results at 8 and 16 weeks did not suggest a consistent trend which may have become significant with continued intervention. In other dietary interventions that ameliorate markers of CVD risk, lipid parameters are frequently modulated after only 2–4 weeks (for example, Cicero *et al.*⁽²⁴⁾, Madsen *et al.*⁽²⁵⁾ and Jenkins *et al.*⁽²⁶⁾), suggesting that the time frame for the present study was more than adequate.

Accordingly, it may be more likely that the lack of effect of the wholegrain food intervention has a biological explanation. In this controlled intervention, we provided study foods in a very specific and structured manner, which may not reflect the consumption of wholegrain foods by habitual whole-grain consumers recorded in observational studies. The range of products was restricted and subjects had to make conscious changes in other parts of their diet in order to incorporate the study foods as prescribed. Breads and breakfast

cereals were the most frequently consumed wholegrain foods and the concomitant increase observed in total dietary carbohydrate intake, plus the addition of food accompaniments such as spreads, milk, etc, may have contributed to the trend towards increased energy intake in the intervention participants. At the highest level of whole-grain intake there was a small but significant reduction (equating to about 0.5 per d reduction of consumption frequency) in fruit consumption, again implying that volunteers may have changed their dietary pattern in order to accommodate the high intake of whole grain required during the second stage of the intervention. These changes may have offset any health benefits of the wholegrain component. The net effect is that the diet of high whole-grain consumers in the present intervention study is different from that of high whole-grain consumers in observational studies, where 'elective' whole-grain intake is a marker of a broader diet and lifestyle that cannot be easily replicated in controlled, intervention studies. However, we believe this type of food-based dietary intervention in free-living, healthy individuals more appropriately models the impact that public health recommendations worded around increasing consumption to prescribed levels of generic wholegrain foods could have on the diet of the general population. Our findings that individuals within the present study tended to alter their diet will be useful in the design of future whole-grain-based dietary intervention studies.

Participants were given a range of wholegrain foods reflecting those generally available in the UK. The term 'whole grain' has been used to describe foods that contain more than 51% whole grain in which the naturally occurring proportions of germ, bran and endosperm are retained⁽²⁷⁾. The majority of the foods provided to participants (see Table 1), with the exception of bread, were not made from finely milled grain, thus it is unlikely that this aspect of processing would have influenced the results. While commercially available wholegrain loaves have similar glycaemic index values to refined loaves⁽²⁸⁾, previous work has shown that increasing the content of intact cereal grains in breads resulted in reduction in glycaemic index⁽²⁹⁾. Several of the other, less processed, foods used in the present study had glycaemic indices lower than that of wholemeal bread.

Finally, the lack of intervention effect may be a consequence of the study population. Pre-screening of participants for those with elevated fasting LDL-cholesterol would have better targeted a population at risk from CVD. However, we did not select a clinically high-risk population for the present study, since the outcomes of this research were based on benefitting dietary guidelines for the population as a whole. Instead, the present study focused specifically on a group of overweight individuals, representative of the population of the UK and other countries where overweight is now the norm, and likely to be at moderately increased risk of CVD (see Table 3). However, the duration of this controlled intervention study represents a very short period of dietary change in the context of lifelong dietary exposures, and may be insufficient to change the lifetime disease trajectory for these individuals with a strong pre-existing risk factor.

Within the present study, we have tested whether infrequent whole-grain consumers respond with improved markers of cardiovascular health when substituting wholegrain food products into their diet, and have found no effect. The present

study sounds a note of caution to the specific health claims for whole grain-rich foods and cardiovascular health. However, it does not undermine more general efforts to promote whole grains as part of a healthy diet for the general population across the life course, based on data from observational studies.

Acknowledgements

This research was fully funded by the UK Food Standards Agency (project N02036). All study foods were kindly provided for the study by UK suppliers (Cereal Partners Worldwide, Weetabix, Allied Bakeries and PepsiCo).

The authors acknowledge the research support provided by Katherine Chan and administrative assistance by Mary Walton. We would also like to acknowledge the effort and time commitment of all WHOLEheart participants, without whom the present study would not have been possible.

C. J. S., S. A. J. and C. M. designed the study, I. A. B. managed participant studies and analysed dietary data and M. C. was the study statistician. D. P. R., P. A. and S. A. K. provided technical support and advice as members of the project steering group. All authors were involved in data interpretation and manuscript preparation.

The authors report no conflicts of interest arising from the present research and its publication.

References

1. Anderson JW (2003) Whole grains protect against atherosclerotic cardiovascular disease. *Proc Nutr Soc* **62**, 135–142.
2. Jacobs DR, Meyer KA, Kushi LH, *et al.* (1998) Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. *Am J Clin Nutr* **68**, 248–257.
3. Liu SM, Stampfer MJ, Hu FB, *et al.* (1999) Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. *Am J Clin Nutr* **70**, 412–419.
4. Liu SM, Manson JE, Stampfer MJ, *et al.* (2000) Whole grain consumption and risk of ischemic stroke in women – a prospective study. *JAMA* **284**, 1534–1540.
5. McKeown NM, Jacques P & Mayer J (2001) Whole grain intake and risk of ischemic stroke in women. *Nutr Rev* **59**, 149–152.
6. Ajani UA, Ford ES & Mokdad AH (2004) Dietary fiber and C-reactive protein: findings from National Health and Nutrition Examination Survey Data. *J Nutr* **134**, 1181–1185.
7. Pereira MA, Jacobs DR, Kushi LH, *et al.* (1998) Whole grain consumption, body weight, fat distribution, and insulin in a bi-racial cohort of young adults: The CARDIA Study. *Circulation* **97**, 18.
8. McKeown NM, Meigs JB, Liu SM, *et al.* (2002) Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study. *Am J Clin Nutr* **76**, 390–398.
9. Food and Drug Administration (2005) Health Claim Notification for Whole Grain Foods with Moderate Fat Content. <http://www.cfsan.fda.gov/~dms/flgrain2.html>
10. Food Standards Agency (2005) Eat well, be well. Helping you make healthier choices. <http://www.eatwell.gov.uk/>
11. Swedish Nutrition Foundation (2003) New Generic Health Claim. <http://www.snf.ideon.se/snf/en/rh/Wholegrain.htm>
12. Truswell AS (2002) Cereal grains and coronary heart disease. *Eur J Clin Nutr* **56**, 1–14.

13. Pereira MA, Jacobs DR, Pins JJ, *et al.* (2002) Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. *Am J Clin Nutr* **75**, 848–855.
14. Andersson A, Tengblad S, Karlstrom B, *et al.* (2007) Whole-grain foods do not affect insulin sensitivity or markers of lipid peroxidation and inflammation in healthy, moderately overweight subjects. *J Nutr* **137**, 1401–1407.
15. Behall KM, Scholfield DJ & Hallfrisch J (2006) Whole-grain diets reduce blood pressure in mildly hypercholesterolemic men and women. *J Am Diet Assoc* **106**, 1445–1449.
16. Katcher HI, Legro RS, Kunselman AR, *et al.* (2008) The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. *Am J Clin Nutr* **87**, 79–90.
17. Kelly SAM, Summerbell CD & Brynes A, *et al.* (2007) Wholegrain cereals for coronary heart disease. *The Cochrane Database of Systematic Reviews* 2007, issue 2, CD005051. <http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005051/frame.html>
18. Life Sciences Research Office (2008) *Whole Grain Intake and Cardiovascular Disease and Whole Grain Intake and Diabetes: A Review*. Bethesda, MD: Life Sciences Research Office.
19. Lang R, Thane CW, Bolton-Smith C, *et al.* (2003) Consumption of whole-grain foods by British adults: findings from further analysis of two national dietary surveys. *Public Health Nutr* **6**, 479–484.
20. Zanchetti A (2003) 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* **21**, 1011–1053.
21. Thane CW, Jones AR, Stephen AM, *et al.* (2007) Comparative whole-grain intake of British adults in 1986–7 and 2000–1. *Br J Nutr* **97**, 987–992.
22. Jebb SA, Cole TJ, Doman D, *et al.* (2000) Evaluation of the novel Tanita body-fat analyser to measure body composition by comparison with a four-compartment model. *Br J Nutr* **83**, 115–122.
23. Brady LM, Gower BA, Lovegrove SS, *et al.* (2004) Revised QUICKI provides a strong surrogate estimate of insulin sensitivity when compared with the minimal model. *Int J Obes* **28**, 222–227.
24. Cicero AFG, Nascetti S, Lopez-Sabater MC, *et al.* (2008) Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related to lipid oxidative damage: The EUROLIVE study. *J Am Coll Nutr* **27**, 314–320.
25. Madsen MB, Jensen AM & Schmidt EB (2007) The effect of a combination of plant sterol-enriched foods in mildly hypercholesterolemic subjects. *Clin Nutr* **26**, 792–798.
26. Jenkins DJA, Kendall CWC, Marchie A, *et al.* (2005) Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. *Am J Clin Nutr* **81**, 380–387.
27. American Association of Cereal Chemists (2005) AACC Definition/Reports: AACC International defines whole grain. <http://www.aaccnet.org/definitions/wholegrain.asp>
28. Foster-Powell K, Holt SHA & Brand-Miller JC (2002) International table of glycemic index and glycemic load values: 2002. *Am J Clin Nutr* **76**, 5–56.
29. Jenkins DJA, Wesson V, Wolever TMS, *et al.* (1988) Wholemeal versus wholegrain breads – proportion of whole or cracked grain and the glycemic response. *BMJ* **297**, 958–960.
30. Wesenberg JC, Carter K, Kadatz D, *et al.* (2000) Evaluation of Dade-Behring, Sigma and Randox homogeneous HDL cholesterol assays on the Dade-Behring Dimension RxL. *Clin Chem* **46**, A94–A94.
31. Nandeesha H, Koner BC, Dorairajan LN, *et al.* (2006) Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. *Clin Chim Acta* **370**, 89–93.
32. Amsel L, Cybulski R & Wessel B (2001) Performance of a revised triglycerides method on the Dade Behring Dimension® clinical chemistry system. *Clin Chem* **47**, A57–A57.
33. Shimizu S, Tani Y, Yamada H, *et al.* (1980) Enzymatic determination of serum-free fatty-acids – a colorimetric method. *Anal Biochem* **107**, 193–198.
34. Savoca R, Jaworek B & Huber AR (2006) New ‘plasma referenced’ POCT glucose monitoring systems – are they suitable for glucose monitoring and diagnosis of diabetes? *Clin Chim Acta* **372**, 199–201.
35. Andersen L, Dinesen B, Jorgensen PN, *et al.* (1993) Enzyme-immunoassay for intact human insulin in serum or plasma. *Clin Chem* **39**, 578–582.
36. Katz A, Nambi SS, Mather K, *et al.* (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* **85**, 2402–2410.
37. Rabasa-Lhoret R, Bastard JP, Jan V, *et al.* (2003) Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states. *J Clin Endocrinol Metab* **88**, 4917–4923.
38. Register TC, Burdon KP, Lenchik L, *et al.* (2004) Variability of serum soluble intercellular adhesion molecule-1 measurements attributable to a common polymorphism. *Clin Chem* **50**, 2185–2187.
39. Garton KJ, Gough PJ, Philalay J, *et al.* (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor- α -converting enzyme (ADAM 17). *J Biol Chem* **278**, 37459–37464.
40. Ruchaud-Sparagano MH, Drost EM, Donnelly SC, *et al.* (1998) Potential pro-inflammatory effects of soluble E-selectin upon neutrophil function. *Eur J Immunol* **28**, 80–89.
41. Webber D, Radcliffe CM, Royle L, *et al.* (2006) Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. *FEBS J* **273**, 3024–3037.
42. Roberts WL, Moulton L, Law TC, *et al.* (2001) Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. *Clin Chem* **47**, 418–425.
43. Wehlin L, Vedin J, Vaage J, *et al.* (2004) Activation of complement and leukocyte receptors during on- and off pump coronary artery bypass surgery. *Eur J Cardiothorac Surg* **25**, 35–42.
44. Al-Barjas HS, Ariens R, Grant P, *et al.* (2006) Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm. *Angiology* **57**, 607–614.
45. Pannekoek H, Veerman H, Lambers H, *et al.* (1986) Endothelial plasminogen-activator inhibitor (PAI) – a new member of the serpin gene family. *EMBO J* **5**, 2539–2544.